Skip to main content

Mouse anti-BRAF antibody VE1 ab228461 is a mouse monoclonal antibody that is used in BRAF western blotting and IHC.

Recombinant format for high batch-to-batch consistency and reproducible results
Validated for BRAF staining on the Leica BOND™ RX automated IHC staining platform
Specificity and sensitivity confirmed in IHC with multi-tissue microarray validation.
Anti-BRAF antibody clone VE1 is cited in over 110 publications


Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-BRAF (mutated V600E) antibody [VE1] (AB228461), expandable thumbnail
  • Western blot - Anti-BRAF (mutated V600E) antibody [VE1] (AB228461), expandable thumbnail
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-BRAF (mutated V600E) antibody [VE1] (AB228461), expandable thumbnail
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-BRAF (mutated V600E) antibody [VE1] (AB228461), expandable thumbnail
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-BRAF (mutated V600E) antibody [VE1] (AB228461), expandable thumbnail

Publications

Key facts

Isotype

IgG2b

Host species

Mouse

Storage buffer

pH: 7.5
Preservative: 0.1% Sodium azide
Constituents: Tris, 0.3% Carrier protein

Form

Liquid

Clonality

Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
WBIHC-P
Human
Tested
Tested
Mouse
Predicted
Predicted
Chicken
Predicted
Predicted

Tested
Tested

Species

Human

Dilution info

1/1000

Notes

-

Predicted
Predicted

Species

Mouse, Chicken

Dilution info

-

Notes

-

Tested
Tested

Species

Human

Dilution info

1/100

Notes

Perform heat mediated epitope retrieval with citrate buffer pH6 before commencing with IHC staining protocol

Predicted
Predicted

Species

Mouse, Chicken

Dilution info

-

Notes

-

Associated Products

Select an associated product type

11 products for Alternative Product

Target data

Function

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179).

Alternative names

Recommended products

Mouse anti-BRAF antibody VE1 ab228461 is a mouse monoclonal antibody that is used in BRAF western blotting and IHC.

Recombinant format for high batch-to-batch consistency and reproducible results
Validated for BRAF staining on the Leica BOND™ RX automated IHC staining platform
Specificity and sensitivity confirmed in IHC with multi-tissue microarray validation.
Anti-BRAF antibody clone VE1 is cited in over 110 publications

Alternative names

Key facts

Isotype

IgG2b

Form

Liquid

Clonality

Monoclonal

Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number

VE1

Purification technique

Affinity purification Protein A

Specificity

The VE1 monoclonal is a sensitive antibody that detects mutated, constitutively active BRAF protein where glutamic acid is present at codon 600 instead of valine (V600E) (PubMed IDs: 21638088, 23657789).

Please be aware that non-specific nuclear staining has been reported with this antibody (PubMed IDs: 23763264, 23589031, 24838325).

Light chain type

kappa

Concentration
Loading...
Purification notes

Purified from TCS by protein A/G.

Storage

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

Notes

The V600E activating mutation in BRAF is found in several cancer types including: ~65% of pleomorphic xanthoastrocytomas, ~52% of microsatellite-unstable colon cancer tumors, ~50% of melanomas, ~35% of papillary thyroid carcinomas and ~5% of microsatellite-stable colon cancers (PubMed IDs: 21274720, 24508103, 18682506, 16024606).

The majority (>90%) of BRAF mutant cancers harbor the V600E mutation. The mutation leads to activation of the MAPK signaling pathway that increases cell invasion and reduces apoptosis. It also leads to reduced expression of melanocyte differentiation antigens and subsequent immune evasion (PubMed IDs: 21638088, 20551059).

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.

This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

BRAF also known as v-Raf murine sarcoma viral oncogene homolog B1 is a protein kinase with a molecular weight of approximately 84 kDa. It is part of the RAF family of kinases which includes A-RAF and C-RAF. BRAF is expressed in various tissues with high expression levels in brain and testis. The protein functions as a serine/threonine kinase pivotal in transmitting signals from the extracellular space to the nucleus therefore influencing cell proliferation differentiation and survival.

Biological function summary

BRAF plays a central role in the MAPK/ERK signaling pathway which regulates cell cycle progression and apoptosis. It forms a part of a complex with other proteins such as RAS following activation. Mutations in BRAF including the common BRAF V600E result in constitutive activation of the pathway leading to uncontrolled cellular processes. This mutated form alters normal signaling enhancing its oncogenic potential.

Pathways

BRAF integrates into the MAPK/ERK and PI3K/AKT pathways which are essential for proper cellular signaling and function. The MAPK/ERK pathway in particular involves cooperation with proteins like MEK and ERK facilitating cellular responses to growth signals. Variants like BRAF V600K and BRAF V600E significantly impact these pathways by aberrantly activating downstream targets without external stimuli promoting oncogenesis.

Associated diseases and disorders

BRAF mutations are critically implicated in melanoma and colorectal cancer. The BRAF V600E mutation for example occurs commonly in melanomas resulting in excessive signaling that drives tumorigenesis. BRAF also connects with proteins such as NRAS and KRAS through these cancers highlighting its role in the broader network of oncogenic signaling. Effective targeting of BRAF and its mutations represents an important strategy in cancer therapy.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

5 product images

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-BRAF (mutated V600E) antibody [VE1] (ab228461), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-BRAF (mutated V600E) antibody [VE1] (ab228461)

    V600E BRAF immunohistochemistry staining of human melanoma using mouse anti-V600E BRAF antibody

    Immunohistochemical analysis of formalin-fixed paraffin-embedded human melanoma tissue (carrying mutant BRAF V600E) labelling BRAF (mutated V600E) with ab228461 at 1/100 dilution. The section was pre-treated using heat-mediated antigen retrieval method with sodium citrate buffer (pH6 epitope retrieval solution 1) for 20mins. The section was then incubated with ab228461 at 1/100 dilution at room temperature and detected using a Leica BOND Polymer refine kit.

  • Western blot - Anti-BRAF (mutated V600E) antibody [VE1] (ab228461), expandable thumbnail

    Western blot - Anti-BRAF (mutated V600E) antibody [VE1] (ab228461)

    False colour image of Western blot: Anti-BRAF (mutated V600E) antibody [VE1] staining at 1/1000 dilution, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab228461 was shown to bind specifically to mutant BRAF V600E. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) at 1/20000 dilution.

    This image was generated in-house using a previous batch, manufactured using hybridoma production method.

    All lanes: Western blot - Anti-BRAF (mutated V600E) antibody [VE1] (ab228461) at 1/1000 dilution

    Lane 1: HCT 116 cell lysate (wildtype BRAF) at 20 µg

    Lane 2: SW480 cell lysate (wildtype BRAF) at 20 µg

    Lane 3: Caco-2 cell lysate (wildtype BRAF) at 20 µg

    Lane 4: HT-29 cell lysate (mutant BRAF V600E) at 20 µg

    Lane 5: A375 cell lysate (mutant BRAF V600E) at 20 µg

    Performed under reducing conditions.

    Predicted band size: 84 kDa

    Observed band size: 85 kDa

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-BRAF (mutated V600E) antibody [VE1] (ab228461), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-BRAF (mutated V600E) antibody [VE1] (ab228461)

    V600E BRAF immunohistochemistry staining of A375 cells using mouse anti-V600E BRAF antibody

    IHC image of BRAF (mutated V600E) staining in a section of formalin-fixed paraffin-embedded A375 cell line (carrying mutant BRAF V600E) performed on a Leica BONDTM system using the standard protocol. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6 epitope retrieval solution 1) for 20mins. The section was then incubated with ab228461 at 5ug/ml for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset secondary-only control image is taken from an identical assay without primary antibody.

    This image was generated in-house using a previous batch manufactured using hybridoma production method.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-BRAF (mutated V600E) antibody [VE1] (ab228461), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-BRAF (mutated V600E) antibody [VE1] (ab228461)

    Negative control cell line image: IHC image of BRAF (mutated V600E) staining in a section of formalin-fixed paraffin-embedded Caco-2 cell line performed on a Leica BONDTM system using the standard protocol. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab228461, 5ug/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset secondary-only control image is taken from an identical assay without primary antibody.

    This image was generated in-house using a previous batch, manufactured using hybridoma production method.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-BRAF (mutated V600E) antibody [VE1] (ab228461), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-BRAF (mutated V600E) antibody [VE1] (ab228461)

    V600E BRAF immunohistochemistry staining of human melanoma using mouse anti-V600E BRAF antibody

    Immunohistochemical analysis of formalin fixed paraffin embedded human melanoma labelling BRAF (mutated V600E) with ab228461 at 1/600 dilution. The immunostaining was performed on a Ventana DISCOVERY ULTRA (Roche Tissue Diagnostics) instrument with an OptiView DAB IHC Detection Kit. Heat mediated antigen retrieval was conducted for 32 mins at 100°C with ULTRA cell conditioning solution (CC1, pH 8.5). ab228461 anti-BRAF (mutated V600E) antibody [VE1] was incubated at 37°C for 16 mins. Sections were counterstained with Hematoxylin II. Image inset shows absence of staining in secondary antibody only control.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com